Skip to main content

Table 2 Demographic and clinical characteristics of the cohort of patients (full dataset)

From: Radiomics based analysis to predict local control and survival in hepatocellular carcinoma patients treated with volumetric modulated arc therapy

Sex Female: 26 (18.4%)
Male: 112 (79.4%)
Age [years] Mean: 64
Median: 66
St.dev: 11
Range: 30–87
Portal Vein Thrombosis No: 64 (46.4%)
Yes: 74 (53.6%)
Tumour location Right lobe: 57 (41.3%)
Left lobe: 10 (7.2%)
Bilateral: 71 (51.4%)
Stage T T1: 8 (5.8%)
T2: 10 (7.2%)
T3: 120 (86.9%)
Stage N N0: 114 (82.6%)
N1: 24 (17.4%)
Stage M M0: 116 (84.1%)
M1: 22 (15.9%)
AJCC Stage I: 7 (5.1%)
II: 9 (6.5%)
III: 83 (60.1%)
IV: 39 (28.3%)
Okuda Stage I: 31 (22.4%)
II: 109 (77.6%)
BCLC Stage A: 9 (6.5%)
B: 29 (21.0%)
C: 100 (72.5%)
Child-Pugh Stage A: 96 (69.6%)
B: 42 (30.4%)
Hepatitis (B/C) No: 19 (13.8%)
Yes: 119 (86.2%)
Initial Alpha-feto protein (ng/mL) Mean: 11481
Range: 2.4, >58300
Dose prescription 54Gy: 16 (11.6%)
60Gy: 114 (82.6%)
66Gy: 8 (5.8%)
  1. Values refer to number of patients, % are relative to the total number of 138 patients